Indevus Comments on Bayer Healthcare Discontinuation of... ( VANTAS(R) to be Only Once-Yearly Impl...)

Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)

Date:12/20/2007

VANTAS(R) to be Only Once-Yearly Implant for Prostate Cancer in U.S. Market

Indevus Reaffirms Commitment to Prostate Cancer Patients

LEXINGTON, Mass., Dec. 20 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today commented on the announcement by Bayer Healthcare that they would discontinue marketing their product Viadur(R) (leuprolide acetate implant), which is indicated for the palliative treatment of advanced prostate cancer. As a result of this announcement, Indevus' product VANTAS(R) (histrelin implant) will be the only 12-month implant for the palliative treatment of advanced prostate cancer. Indevus remains committed to providing patients and physicians effective options for the treatment of advanced prostate cancer.

"Indevus is firmly committed to providing continuity of care for current Viadur patients," stated Kurt W. Lewis, senior vice president, sales and marketing of Indevus. "We will ensure that physicians have ready access to VANTAS, therefore enabling a smooth transition for those patients who desire a once-yearly therapy for the treatment of advanced prostate cancer."

"VANTAS is appropriate for patients who are candidates for long-term LHRH therapy," stated James E. Shipley, M.D., senior vice president clinical development and medical affairs of Indevus. "VANTAS provides the flexibility that only the technology of our once-yearly Hydron Implant can offer, resulting in improved patient compliance and physician efficiency."

More information regarding VANTAS is available at http://www.vantasimplant.com or by calling 888-282-5372.

About VANTAS

VANTAS(R) is a soft and flexible 12-month hydrogel impla
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
6. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court

Post Your Comments:

Indevus Comments on Bayer Healthcare Discontinuation of...( VANTAS(R) to be Only Once-Yearly Impl...)